IRulya Therapeutics Inc.
IRLA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$33.08
KIRA · Stoqly’s AI analyst, in plain words
- IRulya Therapeutics Inc. lost $84.0M in fiscal 2025.
- Free cash flow was −$41.8M in fiscal 2025, — of revenue.
- IRulya Therapeutics Inc. has $17.8M more cash than debt.
Market cap
$203M
P/E
0.5x
Revenue
—
Net income
−$84.0M
Free cash flow
−$41.8M
Operating margin
—
IRulya Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$84.0M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
0.5x
One share costs 0.5 times its yearly profit per share.
What IRulya Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 10, 2026
- Legal name
- IRulya Therapeutics Inc.
- CIK
- 0001662774
IRulya Therapeutics Inc. · IRLA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$89.9M | −$51.7M | −$31.4M | −$56.8M | −$84.0M |
| Diluted EPS | −$3.03 | −$1.54 | −$0.84 | −$1.31 | −$1.68 |
| Cash | |||||
| Cash from operations | −$62.9M | −$44.0M | −$18.3M | −$31.9M | −$41.4M |
| Capital expenditure | $0.2M | $0.1M | $0.2M | $0.3M | $0.4M |
| Free cash flow | −$63.1M | −$44.2M | −$18.5M | −$32.2M | −$41.8M |
| Share count change | 1.9% | 12.7% | 11.2% | 16.2% | 15.8% |
| Debt and strength | |||||
| Cash and short-term investments | $66.5M | $86.2M | $75.1M | $40.8M | $17.8M |
| Debt incl. finance leases | — | $0.0M | $13.4M | $14.3M | $0.0M |
| Shareholders' equity | $119M | $101M | $85.1M | $30.1M | −$35.7M |
| Current ratio | 7.9x | 30.5x | 8.1x | 6.1x | 0.5x |
| Returns and quality | |||||
| Return on capital | — | −285.4% | −116.6% | −1,228.8% | — |
| Return on equity | −61.9% | −47.1% | −33.8% | −98.6% | — |
| Return on tangible equity | −75.8% | −54.6% | −828.8% | — | — |
| Piotroski F-score | — | — | 2 | 1 | 2 |
| Altman Z'' | 3.0 | 25.2 | −3.9 | −11.6 | −21.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
IRulya Therapeutics Inc. · IRLA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $33.08 a share, the company is worth $203M: 0.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001662774). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.